{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.28","upperLimit":"8.54","value":"8.11"},{"comment":"Upper CI limit is not evaluable because there were not enough events at later time to get a reliable upper CI.","groupId":"OG001","lowerLimit":"15.90","upperLimit":"NA","value":"29.63"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"87"}],"units":"Participants"}],"description":"Duration of response (DOR) is defined for participants with an objective response as the time from the first documented objective response to documented disease progression per RECIST v1.1, based on investigator assessment, or death due to any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinded placebo matched to atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).","id":"OG000","title":"Placebo+Gemcitabine+Carboplatin/Cisplatin"},{"description":"Eligible participants received open-label atezolizumab as monotherapy.","id":"OG001","title":"Atezolizumab Monotherapy"}],"paramType":"NUMBER","populationDescription":"The duration of response (DOR)-evaluable population is defined as participants with an objective response in the the ITT population which included only participants concurrently enrolled in Stage 2 and only those who had been randomized at the time of approval of Protocol WO30070 v6.","reportingStatus":"POSTED","timeFrame":"From first documented objective response (CR or PR) to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)","title":"Duration of Response (DOR) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm","type":"SECONDARY","unitOfMeasure":"Months"}